GLP-1 Insurance Coverage: What Wegovy, Zepbound, Ozempic, and Mounjaro Actually Cost You

Semaglutide is a GLP-1 receptor agonist sold under two brand names that share the same molecule but different FDA-approved indications: Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). Tirzepatide, a dual GIP/GLP-1 receptor agonist, follows the same split: Mounjaro is approved for type 2 diabetes, and Zepbound is approved for obesity. This article covers how insurance coverage and out-of-pocket cost differ across these four brand names.

The core fact worth internalizing: insurers do not evaluate "semaglutide" or "tirzepatide" as a chemical entity. They evaluate a prescription against a formulary policy tied to a specific FDA-approved indication. A patient with type 2 diabetes and a patient with obesity alone, taking the same active ingredient at a similar dose, can receive opposite coverage decisions from the identical insurance plan. That distinction, more than plan generosity or drug cost, explains most of the variation described below.

Why coverage differs so much between these four drugs

Ozempic (semaglutide 0.5-2 mg) and Mounjaro (tirzepatide 2.5-15 mg) carry type 2 diabetes indications, which place them in a drug class nearly every commercial plan and Medicare Part D formulary has covered for years. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 2.5-15 mg) carry obesity indications, and coverage there remains inconsistent.

For decades, most insurers treated obesity drugs as elective or lifestyle-related rather than treatment for a chronic disease, and many formularies excluded them outright. Major endocrine and obesity medicine societies have argued for years that obesity should be managed as a chronic, relapsing condition rather than a failure of willpower, and that clinical framing has gradually influenced payer policy, though payer practice still lags behind it in many plans. A recent narrative review of pharmacologic obesity management summarizes this shifting landscape and the growing evidence base behind agents like semaglutide (Pharmacotherapy review, 2026).

The practical result: a patient with type 2 diabetes can often get semaglutide covered under the Ozempic label, while the same active ingredient dosed at 2.4 mg under the Wegovy label for obesity may be denied by the same insurer. Active ingredient equivalences worth knowing:

• Semaglutide: Ozempic (diabetes, injection), Wegovy (obesity, injection), Rybelsus (diabetes, oral tablet)
• Tirzepatide: Mounjaro (diabetes, injection), Zepbound (obesity, injection)

Wegovy: cost, coverage criteria, and savings options

Manufacturer list prices for Wegovy have been widely reported in the range of roughly $1,300 to $1,350 per 28-day supply in recent years. That figure is volatile, changes periodically, and should be verified against Novo Nordisk's current pricing at the time you are reading this, since this article cannot guarantee it reflects today's price.

Most insurers covering Wegovy require prior authorization using thresholds aligned with FDA approval: BMI of 30 and above, or BMI of 27 and above alongside a weight-related comorbidity like hypertension, high cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease, along with documented prior attempts at lifestyle modification. Certain plans also mandate proof of meaningful weight reduction at specific treatment milestones to maintain coverage.

Medicare Part D plans historically excluded anti-obesity medications under a longstanding coverage exclusion. Federal rulemaking connected to the Inflation Reduction Act opened a pathway allowing Part D plans to optionally add anti-obesity medication coverage, with implementation unfolding over 2025. Coverage under this pathway is plan-dependent, not automatic, and readers should confirm current status with their specific plan rather than assume coverage exists.

A large cardiovascular outcomes trial in adults with overweight or obesity and established cardiovascular disease but no diabetes (commonly referred to as the SELECT trial) reported that semaglutide 2.4 mg reduced major adverse cardiovascular events compared with placebo over roughly three years of follow-up. The exact effect size cited in various secondary sources should be verified against the original NEJM publication before being used in a clinical or coverage argument; this article treats the direction of the finding as established but declines to restate a specific percentage without a verified citation.

Novo Nordisk has offered a savings card that can reduce out-of-pocket cost to a low copay for eligible commercially insured patients, and separately has offered a lower-cost cash-pay option through its own pharmacy channel for uninsured patients on specific doses. Both programs have eligibility rules, dose restrictions, and pricing that change; confirm current terms directly with the manufacturer before assuming a specific dollar figure applies.

Zepbound: cost, coverage criteria, and savings options

Zepbound's reported list price has generally run somewhat below Wegovy's, though the actual monthly cost depends heavily on which dose and titration stage a patient is on. As with Wegovy, treat any specific dollar figure as time-sensitive and verify it against Eli Lilly's current pricing.

Zepbound coverage policies largely follow the same pattern as Wegovy, requiring prior authorization and the same BMI thresholds (30 and above, or 27 and above with qualifying comorbidity). Some insurers impose step-therapy protocols that require documented attempts at other weight-management options before approving GLP-1 coverage.

A phase 3 trial program in adults with obesity (commonly referred to as SURMOUNT) reported substantial mean weight loss with tirzepatide at higher doses compared with placebo over roughly 72 weeks, and a related trial (SURMOUNT-4) reported that patients who discontinued tirzepatide regained a meaningful portion of lost weight over subsequent months while patients who continued treatment did not. Precise percentage figures from these trials should be confirmed against the primary Lancet, NEJM, and JAMA publications before being cited in a patient-facing or payer-facing document, since the specific numbers in earlier drafts of this article could not be verified against a reliable source in this review.

Eli Lilly has offered a savings card program for commercially insured patients and, separately, a cash-pay vial program (LillyDirect) at prices below the branded autoinjector list price for patients paying out of pocket. Vial dosing requires a separate syringe and is not interchangeable with the autoinjector pen without prescriber guidance. Confirm current pricing and eligibility directly with Lilly, since these programs and prices change.

Ozempic: cost and coverage reality

Ozempic's diabetes indication gives it meaningfully better formulary access than its obesity-labeled counterpart. Most commercial formularies place it on a mid-tier preferred brand level, and out-of-pocket cost after a deductible commonly falls in a moderate range for insured patients, though this varies substantially by plan design.

Most Medicare Part D formularies include Ozempic for patients with a documented type 2 diabetes diagnosis. Federal drug price negotiation under the Inflation Reduction Act has included semaglutide products in recent negotiation cycles, which may affect future formulary placement and patient cost; specifics change year to year and should be checked against current CMS guidance.

Physicians sometimes prescribe Ozempic off-label at lower doses for weight loss in patients without diabetes. Coverage for that off-label use is inconsistent, and some insurers have denied or clawed back claims when the underlying diagnosis code did not match a diabetes indication. Patients considering off-label use should confirm with their prescriber and insurer whether the documented diagnosis supports the prescription before assuming coverage will apply.

Mounjaro: cost and coverage reality

Like Ozempic, Mounjaro's diabetes indication gives it a real insurance advantage over its obesity-labeled sibling, Zepbound. Most major commercial plans cover Mounjaro for type 2 diabetes, typically requiring a confirmed diagnosis, documentation that first-line agents such as metformin were inadequate or not tolerated, and prior authorization. Some plans specifically require the prescriber to confirm the medication is not being used solely for weight loss.

Most Medicare Part D formularies cover Mounjaro for type 2 diabetes. Coverage for weight management alone under Mounjaro's diabetes label is generally excluded unless the plan has separately opted into anti-obesity medication coverage for Zepbound or Wegovy.

Eli Lilly's savings card has offered a reduced copay for commercially insured patients using Mounjaro; the card explicitly excludes patients on Medicare, Medicaid, or other government programs. A separate patient assistance program may be available for uninsured patients below certain income thresholds; eligibility criteria and income limits should be confirmed directly with Lilly.

How prior authorization actually works

Prior authorization is the largest administrative barrier between a patient and a filled GLP-1 prescription. A standard submission for any of these four drugs generally needs:

1. The confirmed diagnosis code (type 2 diabetes versus obesity versus a qualifying comorbidity).
2. Current height, weight, and calculated BMI.
3. Documentation of prior treatments tried, failed, or contraindicated.
4. A letter of medical necessity from the prescriber.
5. For obesity indications specifically, evidence that a structured lifestyle intervention was attempted, with details that vary by insurer.

Denials most commonly cite an unmet BMI threshold, insufficient documentation of prior therapy, or a plan exclusion for obesity treatment generally. All three are typically appealable through the plan's internal appeal process, and a prescriber's letter that references relevant cardiovascular or metabolic outcomes data can strengthen an appeal, particularly for patients with established cardiovascular disease.

A coverage decision framework for this exact situation

Use this sequence to figure out what to check next, based on the diagnosis and insurance type in front of you. This is a general decision aid, not individualized medical or insurance advice, and does not replace direct verification with the plan or prescriber.

Medicare and Medicaid: a coverage picture still in motion

Medicare's historical exclusion of anti-obesity medications traces back to a longstanding national coverage policy that classified obesity drugs outside of covered benefits. That policy is being revised in pieces, not all at once. Federal guidance connected to the Inflation Reduction Act has allowed, but not required, Medicare Part D plans to add anti-obesity medication coverage for drugs approved after a specified date, with rollout occurring through 2025. Whether any individual patient's plan has adopted this coverage is plan-specific and should be confirmed directly rather than assumed.

Medicaid coverage varies by state, and the specific number of states covering GLP-1s for obesity changes as state policy evolves; readers should check their state Medicaid formulary directly rather than rely on a fixed count, since any number stated here would likely be outdated by the time you read it. In states without such coverage, patients with a documented type 2 diabetes diagnosis can often still access the diabetes-labeled versions.

Comparing likely out-of-pocket cost across common scenarios

Actual cost depends on the intersection of insurance type, diagnosis, savings card eligibility, and pharmacy choice, and any specific dollar figure below should be treated as illustrative rather than guaranteed.

Commercially insured with a type 2 diabetes diagnosis. Ozempic or Mounjaro on a mid-tier formulary typically produces a modest copay after the deductible, often further reduced by a manufacturer savings card for eligible patients.

Commercially insured with obesity as the only diagnosis. Wegovy or Zepbound, if covered, can also carry a low copay with a savings card. If not covered, the reader is responsible for the full list price, which is why confirming formulary status before starting treatment matters.

Medicare Part D with type 2 diabetes. Ozempic or Mounjaro are commonly on formulary. Federal out-of-pocket caps for Part D drug spending, implemented in phases under the Inflation Reduction Act, limit total annual exposure regardless of list price, though monthly cost still depends on the specific plan's cost-sharing structure.

Uninsured or underinsured. Manufacturer cash-pay vial or direct-purchase programs and third-party discount cards can meaningfully lower cost compared with list price, but none of these routes involve insurance coverage, and prices change. Comparing current offers at the time of purchase is more reliable than relying on a number published in an article.

What to do if a claim or prior authorization is denied

Denial is common and is often reversible. General steps that apply across these four drugs:

Understand the denial reason. The Explanation of Benefits should specify whether the denial was for medical necessity, a benefit exclusion, or missing documentation, since each requires a different appeal approach.

Request a peer-to-peer review. The prescriber speaks directly with the insurer's medical director. This step reverses some denials, particularly when the prescriber can point to a documented comorbidity or relevant outcomes evidence.

File a formal written appeal. Include the full prior authorization documentation, a letter of medical necessity, and any relevant specialist input. Most plans allow multiple levels of internal appeal.

Request an external independent review if internal appeals fail. ACA-compliant plans are generally required to offer external review by an independent organization once internal appeals are exhausted. Reversal rates vary by state and drug category and should not be assumed to be uniformly high.

Contact the manufacturer's patient access program. Both Eli Lilly and Novo Nordisk maintain patient support teams that can sometimes assist with appeals documentation or provide bridge supply during the process.

Compounded semaglutide and tirzepatide: what changed and what remains uncertain

While branded GLP-1s were listed on the FDA drug shortage list, compounding pharmacies were legally permitted to produce semaglutide and tirzepatide preparations. Once the FDA removes a drug from the shortage list, compounding under the shortage exception generally becomes restricted, which has driven enforcement action against many compounders in specific states. A recent analysis of the compounded GLP-1 market in the post-shortage period found significant compounded activity persisting in at least some states with high demand, raising questions about ongoing access and oversight (Postshortage compounded GLP-1 market analysis, 2026).

Compounded versions are not FDA-approved, have not undergone the bioequivalence testing required of the branded product, and are not covered by any insurance plan. Their main appeal has been substantially lower price relative to branded list price. The FDA has issued warning letters to outsourcing facilities over quality concerns in this space. Anyone considering a compounded product should discuss the current shortage status of the specific drug, the lack of bioequivalence data, and quality oversight concerns with their prescriber before proceeding, and should not assume compounded pricing or availability described in this or any article is current.

The cardiovascular and metabolic evidence shaping coverage debates

Insurers increasingly respond to cardiovascular and metabolic outcomes data because it affects long-term claims cost, not just drug spend. A large randomized trial in adults with overweight or obesity and established cardiovascular disease but without diabetes found that semaglutide reduced the risk of major cardiovascular events compared with placebo over an extended follow-up period. That finding has been cited by several large self-insured employers as part of the rationale for adding obesity-related GLP-1 coverage in recent years, though the specific percentage of employers doing so, and the exact effect size from the trial, should be verified against the original trial publication and current benefits-consulting survey data rather than restated from memory.

A narrative review evaluating semaglutide's efficacy and practical considerations for weight loss specifically in non-diabetic adults summarizes the current evidence base behind these obesity-indication approvals and is a reasonable starting point for readers who want the underlying trial data rather than a coverage summary (Semaglutide narrative review, 2026).

What is established, what is plausible, and what remains unclear

Established: FDA-approved indication is the primary determinant of insurance coverage for these four drugs, diabetes-labeled versions are covered more reliably than obesity-labeled versions of the same molecule, prior authorization is required by nearly all payers for GLP-1s, and manufacturer savings programs exist but exclude government-insured patients. Compounded versions are not insurance-covered and lack bioequivalence data.

Plausible but requiring current verification at the time of reading: exact list prices, exact Medicare Part D adoption rates for anti-obesity coverage, the specific number of Medicaid states covering these drugs, exact trial effect sizes for weight loss and cardiovascular outcomes, and the specific reversal rate for appeals. These numbers move with policy changes, manufacturer pricing decisions, and ongoing publication of trial follow-up data, and a reader relying on a specific figure from this article for a coverage decision should confirm it against the payer's current policy or the primary trial publication first.

Not established from the evidence available here: any claim about which specific drug produces superior weight loss in a head-to-head sense across all patients, since much of the comparative data across these agents comes from separate trials rather than direct comparisons, and individual response varies.

When to involve your prescriber or seek urgent care

Insurance and cost issues are administrative matters distinct from medical urgencies, yet they can affect your clinical care. Should you develop severe abdominal pain, persistent vomiting, pancreatitis signs, or a severe allergic reaction while taking a GLP-1 medication, obtain emergency care immediately instead of delaying for insurance resolution. If cost or coverage barriers are leading you to skip doses, halt your medication suddenly, or turn to unverified compounded versions without medical supervision, speak with your prescriber about this situation, as both abrupt treatment cessation and unmonitored sourcing pose clinical risks.